| ||
| First-line erlotinib in advanced non-small cell lung cancer (NSCLC ... First-line erlotinib in advanced non-small cell lung cancer (NSCLC) carrying an activating EGFR mutation: A multicenter academic phase II study in Caucasian ... www.asco.org/ASCOv2/Meetings/Abstracts?&...abst... | ||
| Synta Announces Ganetespib Phase 2 Non-small Cell Lung Cancer ... 75% of patients with ALK+ and 62% of patients with KRAS-mutant tumors show tumor shrinkage in target lesions - - Overall disease control rate of 54% ... article.wn.com/.../Synta_Announces_Ganetespib_Phase_2_No... |
Tip: Use a minus sign (-) in front of terms in your query that you want to exclude. Learn more.
Remove this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment